Tel Aviv, May 23, 2017 – As part of his mission to Israel, the Premier of Quebec announced today an agreement between the Hebrew University of Jerusalem and the University of Montreal. It includes the development of new projects in collaboration with the Institute for Research in Immunology and Cancer (IRIC) in the fields of structural biology, molecular pharmacology and drug discovery.
This announcement took place during an historic mission for Quebec’s government: the first visit of a Premier of Quebec in Israel and the West Bank.
Three representatives from the University of Montreal and IRIC, Michel Bouvier (Deputy Vice-Rector Research, Discovery, Creation and Innovation – University of Montreal and Chief Executive Officer– IRIC), Nadine Beauger (Chief Executive Officer – Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and Steven Klein (Vice-President, Business Development – IRICoR) are accompanying the Premier of Quebec, Philippe Couillard, Dominique Anglade, Quebec’s Minister of Economy, Science and Innovation and Minister responsible for the Digital Strategy, as well as more than 100 representatives of Quebec businesses and institutions.
Michel Bouvier expressed his delight for such an agreement that broadens the existing accord between the two universities, notably through their respective law faculties. “This collaboration, which insures the international influence of IRIC’s Investigators and the University of Montreal, will most certainly lead to scientific progress and high potential impact initiatives over the next few years.”
Nadine Beauger, on the other hand, is pleased to be a part of this mission which provides international visibility to IRIC’s Investigators and stimulates the development of partnerships to develop new therapeutic solutions.
This economic mission follows the recent announcements of a series of strategies proposed by the Quebec Government in the past months to stimulate science advancement.
Mr. Bouvier, Ms. Beauger and Mr. Klein will be in Israel for the entire duration of the mission ending on Thursday, May 25th.
Ms. Dominique Anglade, Quebec’s Minister of Economy, Science and Innovation and Minister responsible for the Digital Strategy, Mr. Michel Bouvier, Deputy Vice-Rector Research, Discovery, Creation and Innovation – University of Montreal and Chief Executive Officer– IRIC, Mr. Philippe Couillard, Premier of Québec
About the University of Montreal
Deeply rooted in Montreal and dedicated to its international mission, the University of Montreal is one of the top 100 universities in the world. It was founded in 1878, and together with its two affiliated schools, HEC Montréal and Polytechnique Montréal, constitutes the largest centre of higher education and research in Quebec and one of the major centres in North America. The University of Montreal brings together more than 2,700 professors and researchers and welcomes more than 68,000 students. umontreal.ca
About the Institute for Research in Immunology and Cancer
An ultra-modern research hub and training centre located in the heart of the Université de Montréal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer.
For more information: www.iric.ca/en/
About the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)
As Université de Montréal’s drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive technologies to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR: www.iricor.ca
– 30 –
| For further information
Catherine Cardinal Chief, Communication and media relations 514 343-6111, ext 41299 |
Cristina Annunzi Advisor, Communication and media relations 514 343-7283 |